Karatepe Celalettin, Aitinay Levent, Yetim Tulin Durgun, Dagli Celalettin, Dursun Suat
Mustafa Kemal University, Cardiovascular Surgery Department, Antakya - Turkey.
J Vasc Access. 2013 Jul-Sep;14(3):273-80. doi: 10.5301/jva.5000145. Epub 2013 Apr 16.
The use of tunneled central venous catheters (CVC) as vascular access for hemodialysis treatment is increasing worldwide. We present a novel polycarbonate urethane nano-fabric graft, produced by electrospinning technology, which has self-sealing features that avoid seroma formation and allow puncturing within 48 hours. The aim of this study was to assess its advantages in a setting where late referral is common.
METHODS: A retrospective single center study assessed 24 implanted grafts in 24 patients with maximal follow-up of 18 months; patency rates, time to first cannulation and post-operative complications were assessed.
Successful access was achieved in all 24 patients within 48 hours. In 50% of the patients cannulation was performed within 24 hours without increasing the complication rate. Twelve month primary and secondary patencies were 50% and 70.8%, respectively. Excluding early failures (within 30 days) because of surgical problems, 12 month primary and secondary patencies were 75% and 81.2% respectively. Complication and infection rates were 10.94 and 0.49/1000 dialysis procedures, respectively. No pseudoaneurysms or seromas were documented at 18 months.
Early cannulation was successful in all patients with good 12-month primary and secondary patency rates, compared to data reported by others on polytetrafluoroethylene (PTFE) grafts. The infection rate was substantially lower than in tunneled CVCs. Therefore, the AVflo graft may improve the clinical status of dialysis patients by decreasing the exposure to CVCs.
在全球范围内,使用带隧道的中心静脉导管(CVC)作为血液透析治疗的血管通路的情况正在增加。我们展示了一种通过静电纺丝技术生产的新型聚碳酸酯聚氨酯纳米纤维移植物,它具有自密封特性,可避免血清肿形成,并允许在48小时内进行穿刺。本研究的目的是评估其在晚期转诊常见情况下的优势。
一项回顾性单中心研究评估了24例患者植入的24个移植物,最长随访18个月;评估通畅率、首次插管时间和术后并发症。
所有24例患者均在48小时内成功建立通路。50%的患者在24小时内进行了插管,且未增加并发症发生率。12个月的初级和次级通畅率分别为50%和70.8%。排除因手术问题导致的早期失败(30天内),12个月的初级和次级通畅率分别为75%和81.2%。并发症和感染率分别为10.94和0.49/1000次透析程序。18个月时未记录到假性动脉瘤或血清肿。
与其他人报道的聚四氟乙烯(PTFE)移植物的数据相比,所有患者早期插管均成功,12个月的初级和次级通畅率良好。感染率明显低于带隧道的CVC。因此,AVflo移植物可能通过减少接触CVC来改善透析患者的临床状况。